alpha 1-antitrypsin

AbbVie Invests $195 Million in New North Chicago API Manufacturing Site

4 weeks ago talkbio0Tagged AbbVie, alpha 1-antitrypsin, domestic production, expansion, Facility (object), Illinois (geographic location), Investments, Manufacturing, North Chicago, pharmaceutical manufacturing

AbbVie; North Chicago; API manufacturing; $195 million investment; facility expansion; pharmaceutical manufacturing; Illinois; domestic production

FDA Launches PreCheck Program to Accelerate Domestic Drug Manufacturing

1 month ago talkbio0Tagged alpha 1-antitrypsin, Construction worker, domestic drug manufacturing, Facility (object), National Security, Pharmaceutical Supply Chain, PreCheck, regulatory streamlining, Trump administration, United States Food and Drug Administration

FDA PreCheck; domestic drug manufacturing; pharmaceutical supply chain; API; regulatory streamlining; facility construction; national security; Trump administration

Trump Tariffs Poised to Hit Drug Tool and Packaging Manufacturers: Industry Faces Rising Costs and Supply Chain Challenges

5 months ago talkbio0Tagged alpha 1-antitrypsin, Biopharma trade war, Drug Industry, Drug packaging industry, Generic Drugs, Impact food supplement, lobbying, Manufacturing, Market, onshoring, Pharmaceutical Supply Chain, pharmaceutical tariffs, Supply chain disruption, Trump tariffs, U.S., United States

Trump tariffs , Drug packaging industry , Pharmaceutical supply chain , API manufacturing costs , Biopharma trade war , U.S. manufacturing onshoring , Generic drugs market impact , Pharmaceutical tariffs , Supply chain disruption , Pharmaceutical industry lobbying

Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

6 months ago talkbio0Tagged alpha 1-antitrypsin, Capacity, Contract agreement, CordenPharma, Fill/finish, GLP-1/GIP Dual Agonist, Obesity, oral formulations, production, subcutaneous, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations